Medical Irradiation Market Report 2026

The medical irradiation market size has grown rapidly in recent years. It will grow from $1.96 billion in 2025 to $2.24 billion in 2026 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to growth in cancer incidence rates, adoption of radiotherapy in oncology care, expansion of diagnostic imaging services, advancements in radiation delivery systems, increased healthcare infrastructure investments.

The medical irradiation market size is expected to see rapid growth in the next few years. It will grow to $3.77 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to rising demand for precision cancer treatments, increasing awareness of early disease diagnosis, expansion of specialized therapy centers, growing geriatric population, continuous improvements in radiation safety standards. Major trends in the forecast period include rising adoption of targeted radiation therapies, growing use of irradiation in diagnostic imaging, increased focus on precision and dose optimization, expansion of radiation-based cancer treatment programs, higher emphasis on patient safety and regulatory compliance.

The increasing prevalence of cancer is expected to drive the growth of the medical irradiation market in the coming years. Cancer is a condition characterized by uncontrolled cell growth, affecting various organs and causing significant morbidity and mortality worldwide. Medical irradiation plays a vital role in cancer treatment by using targeted radiation to damage or eliminate cancer cells while minimizing harm to healthy tissues. For example, according to a report by the Leukemia & Lymphoma Society, a US-based non-profit health organization, in 2023, approximately 184,720 individuals in the US are expected to be diagnosed with leukemia, lymphoma, or myeloma. In total, an estimated 1,958,310 new cancer cases are anticipated in the US in 2023, with leukemia, lymphoma, and myeloma likely accounting for 9.4% of these cases. Thus, the rising prevalence of cancer is contributing to the expansion of the medical irradiation market.

Major companies operating in the medical irradiation market are developing innovative solutions, such as the Premium Dual-Energy Mobile System, to gain a competitive edge. A Premium Dual-Energy Mobile System is a high-end medical imaging device that combines dual-energy technology for improved diagnostic capabilities while offering mobility across various clinical settings, delivering advanced imaging solutions at the point of care. For example, in July 2023, KA Imaging, a Canada-based manufacturer, introduced its Reveal Mobi Pro dual-energy mobile X-ray system. The Reveal Mobi Pro is a complete mobile X-ray solution that integrates SpectralDR technology with KA Imaging's Reveal 35C detector. At the bedside, Reveal's ability to capture dual-energy and conventional images simultaneously with a single exposure enhances outcomes for patients and hospitals while protecting revenue by reducing expenses.

In March 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for an undisclosed amount. Through this acquisition, AstraZeneca intends to strengthen its oncology pipeline and expand targeted radiopharmaceutical capabilities by incorporating Fusion Pharmaceuticals’ expertise in precision cancer therapies. Fusion Pharmaceuticals Inc. is a Canada-based biotechnology company focused on developing targeted radiopharmaceutical therapies for oncology applications.

Major companies operating in the medical irradiation market are Hitachi Ltd., Toshiba Corporation, Siemens Healthcare GmbH, Koninklijke Philips N.V., GE Healthcare Company, Mayo Clinic Health System, Canon Medical Systems R&D (Dalian) Co. Ltd., Varian Medical Systems Inc., Elekta AB, Accuray Incorporated, Ion Beam Applications S.A., Brainlab AG, ViewRay Technologies Inc., Mevion Medical Systems Inc., RaySearch Laboratories AB, NTP Radioisotopes SOC Ltd., RefleXion Medical Inc., Vision RT Ltd., Sun Nuclear Corporation, Eckert & Ziegler BEBIG GmbH, C-RAD AB, Panacea Medical Technologies Pvt. Ltd., Standard Imaging Inc., CIVCO Radiotherapy Inc., IntraOp Medical Corporation, RTsafe Solutions Ltd., Mirada Medical Corporation.

North America was the largest region in the medical irradiation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medical irradiation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medical irradiation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs impact the medical irradiation market by increasing costs of imported radiation equipment, shielding materials, and specialized components. Hospitals and therapy centers in north america, europe, and asia-pacific are most affected due to dependence on advanced foreign technologies. Higher tariffs can slow equipment upgrades and raise treatment costs. At the same time, they encourage local manufacturing and regional sourcing, supporting long-term market stability.

The medical irradiation market research report is one of a series of new reports that provides medical irradiation market statistics, including medical irradiation industry global market size, regional shares, competitors with a medical irradiation market share, detailed medical irradiation market segments, market trends and opportunities, and any further data you may need to thrive in the medical irradiation industry. This medical irradiation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Medical irradiation involves the controlled application of radiation for therapeutic purposes, particularly in cancer treatment, where precise doses are used to damage or eliminate targeted cells while limiting harm to surrounding healthy tissue. It is also used in diagnostic applications to generate images of internal organs or physiological functions, supporting the detection and diagnosis of a wide range of medical conditions.

The disease types associated with medical irradiation include trisomy 21, translocation medical irradiation, and mosaic medical irradiation. Trisomy 21 is a genetic disorder marked by the presence of an additional copy of chromosome 21, which results in Down syndrome. Treatment types are broadly classified into two categories: diagnosis and therapy. Distribution channels consist of direct tenders, retail sales, and others. The end users include hospitals, clinics, homecare environments, therapy centers, and others.

The medical irradiation market includes revenues earned by entities by providing services such as diagnostic imaging services, radiation therapy, radiopharmaceutical and radiation safety, and dosimetry services. The market value includes the value of related goods sold by the service provider or included within the service offering. The medical irradiation market consists of sales of products such as radiation therapy equipment, diagnostic imaging devices, radiopharmaceuticals, and nuclear medicine devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.